The role of glyoxalase system in methylglyoxal detoxification. by MohammedBashar Al-Qazzan (22439236)

Subjects:

IC₅₀ values (mean ±SD in μM) of <i><i>in vitro</i></i> DPPH-radical scavenging properties vs. ascorbic acid and antiinflammation propensities vs. indomethacin of the tes... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Shikonin diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Classification of inactive compounds. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Active compounds identified as glyoxalase-I inhibitors. by MohammedBashar Al-Qazzan (22439236)

Subjects:

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Tolcapone diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs. by Aga E. Gelgie (17661720)

Subjects:

Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

Subjects:

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

Subjects:

Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

Subjects:

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Subjects:

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Subjects:

Open data. by Larissa Brazolotto Ferreira (17671168)

Subjects:

Cell cycle analysis of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Subjects:

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Subjects: